Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial

What Was Tested

The paper reports a study of Vasopressin, published as a randomized controlled trial.

Autosomal dominant polycystic kidney disease (ADPKD) affects millions of people worldwide.

Small sample size and short follow-up.

Who Took Part

The abstract describes 34 patients taking part.

PubMed indexes the participants as teenagers, young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized and pilot.

Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.

It is described as a pilot, a small early test of whether a larger Vasopressin study would be practical.

A randomized controlled trial with equal (1:1) allocation.

Fasting plasma copeptin level, 24-hour urine osmolality, and total solute intake.

What Was Measured

Topics PubMed links to this paper include Arginine Vasopressin, Drinking, Osmolar Concentration, Pilot Projects and Polycystic Kidney, Autosomal Dominant.

Author keywords: Autosomal dominant polycystic kidney disease (ADPKD), clinical trial, copeptin, nutrition, osmolality and protein.

What This Means in Plain Language

The paper is a randomized and pilot study of Vasopressin in 34 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (American journal of kidney diseases : the official journal of the National Kidney Foundation), a journal based in United States.

More context: the Vasopressin compound page, all human trials.